Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality

Table 4 Crude rates and adjusted relative hazards of doubling of creatinine and USRDS-documented progression to end-stage renal disease (ESRD) after liver transplantation, according to mean uric acid level in the first quarter after transplantation

	Events	Person- years	Crude rate ^a		Adjusted ^b Relative Hazard
Characteristic	Events	Person- years	Crude rate ^a	p-value	HR	[95% C.I.]	p-value
Outcome: doubling of creatinine
All Patients (n = 300)				0.24
Uric Acid <6.5 mg/dl	81	361	224.3		1.0	Reference
Uric Acid ≥6.5 mg/dl	99	370	267.3		0.9	[0.7, 1.3]	0.70
Uric Acid (+1 mg/dl increase)					0.96	[0.90, 1.03]	0.30
Analysis stratified by diabetes
Non-diabetics(n = 221)				0.86
Uric Acid <6.5 mg/dl	63	252	249.5		1.0	Reference
Uric Acid ≥6.5 mg/dl	69	268	257.2		0.8 ^c	[0.5, 1.1]	0.15
Uric Acid (+1 mg/dl increase)					0.92 ^d	[0.84, 0.99]	0.04
Diabetics(n = 79)				0.014
Uric Acid <6.5 mg/dl	16	100	160.7		1.0	Reference
Uric Acid ≥6.5 mg/dl	29	85	341.1		2.2 ^c	[1.1, 4.3]	0.025
Uric Acid (+1 mg/dl increase)					1.1 ^d	[1.00, 1.31]	0.049
Outcome: Progression to ESRD
All Patients (n = 300)				0.31
Uric Acid <6.5 mg/dl	16	844	18.9		1.0	Reference
Uric Acid ≥6.5 mg/dl	19	845	22.5		0.9	[0.4, 1.7]	0.70

^a Events (doubling of Scr or progression to ESRD, respectively) per 1000 person-years of follow-up
^b All models include age, gender, and time-dependent eGFR category
^c p-_interaction = 0.061
^d p-_interaction = 0.042. No interactions with eGFR or diabetes were seen in the association between UA and ESRD, and no interactions with eGFR were seen for doubling of creatinine

ISSN: 1471-2369